Discontinuation is more efficacious than tapering of anti-TNF therapy in maintaining low disease activity (LDA) or remission status in patients with axial spondyloarthritis, according to a systematic review of 13 studies. Although the researchers assess the level of evidence as weak, discontinuation of anti-TNF therapy (in five studies) led to flare in 76–100% of patients, whereas tapering by reducing the frequency of anti-TNF administration (in eight studies) enabled 53–100% of patients to maintain LDA or remission.